Clinical Trials Logo

Filter by:
NCT ID: NCT02276053 Completed - Clinical trials for Brain Tumor Related Epilepsy (BTRE)

Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

VIBES
Start date: November 27, 2014
Phase:
Study type: Observational

This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is effective in routine clinical practice for patients with epilepsy caused by a brain tumor.

NCT ID: NCT02274857 Completed - Clinical trials for Persistent Atrial Fibrillation

Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures

REAFFIRM
Start date: October 2014
Phase: N/A
Study type: Interventional

The study is a prospective, multicenter, randomized study to assess the safety and effectiveness of FIRM procedures followed by conventional ablation including PVI versus a standard PVI procedure for the treatment of persistent atrial fibrillation (AF).

NCT ID: NCT02273713 Completed - Esophageal Cancer Clinical Trials

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)

ACTION
Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Oesophagogastric cancer is a major cause of cancer related mortality, with an overall 5-year survival rate of 10% worldwide and patients are often diagnosed with locally advanced or metastasized disease at first presentation. For advanced oesophagogastric cancer fluoropyrimidines are the backbone of palliative chemotherapy and is commonly used in 2- or 3-drug combinations . However, in clinical practice after progression on first line therapy, a substantial number of oesophagogastric cancer patients may not be able to start second line chemotherapy due to rapid clinical deterioration. Therefore, new triplets with high anti-tumor activity and low toxicity are urgently needed. Given the activity of capecitabine and oxaliplatin containing regimens and the potential of taxanes in oesophagogastric cancer, the investigators propose a phase I study combining capecitabine and oxaliplatin with Nab-paclitaxel. Solvent-based taxanes (paclitaxel, docetaxel) can cause severe toxicities not only by the active agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane) is a solvent-free formulation of paclitaxel encapsulated in albumin. It does not require premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated hypersensitivity reactions. This new formulation improves safety profile, allows higher dosing with shorter infusion duration, and produces higher tumor drug concentration. It has proven activity in breast cancer, non small lung cancer and pancreatic cancer, as well as in gastric cancer models.

NCT ID: NCT02273141 Completed - Colorectal Cancer Clinical Trials

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.

Start date: November 2014
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy, safety and tolerability of NER1006 versus a sodium picosulfate and magnesium salt solution (SP + MS) in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a Day Before Only Dosing regimen. Approximately 484 patients will be randomised with the aim of achieving a minimum of 220 patients in each of the 2 groups.

NCT ID: NCT02272985 Completed - Clinical trials for Haemodialysis-induced Symptom

Cerebral Blood Flow During Hemodialysis

Start date: April 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of the hemodialysis procedure on cerebral blood flow (CBF) in elderly maintenance hemodialysis (HD) patients. The investigators hypothesize that HD induced blood pressure changes are associated with a fall in global and/or regional CBF during HD. Second, the investigators hypothesize that near infrared spectroscopy (NIRS) will correlate with CBF measured by[15O]H2O PET.

NCT ID: NCT02272790 Completed - Clinical trials for Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: January 30, 2015
Phase: Phase 2
Study type: Interventional

Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.

NCT ID: NCT02272296 Completed - Diabetes Mellitus Clinical Trials

Reliability of Insulin by Jet Injection

Start date: February 2015
Phase: Phase 4
Study type: Interventional

Using a specific jet injector for the administration of a rapid-acting insulin analogue has been shown to advance the absorption of insulin from the subcutaneous area into the bloodstream by 40-50%, when compared to conventional injection by insulin pens. The reproducibility of the jet stream method has not been previously determined in vivo. It is also unknown how the efficacy of injecting regular insulin by jet stream compares to that of rapid-acting analogues injected by conventional pen. Objectives: 1. To compare the pharmacologic reproducibility of the rapid-acting insulin analogue aspart (Novorapid®) injected by jet-injection to that of the same insulin injected with a conventional pen. 2. To compare pharmacokinetic and -dynamic profile of regular insulin injected by jet injection to that of aspart insulin injected by conventional pen. Study design: Double-blind double-dummy randomized controlled parallel/cross-over

NCT ID: NCT02271997 Completed - Iron Deficiency Clinical Trials

Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass

Ironsuppletion
Start date: December 4, 2014
Phase: Phase 4
Study type: Interventional

Multicentre randomized controlled trial to evaluate the optimal treatment for patients who developed an iron deficiency after Roux-en-Y Gastric bypass.

NCT ID: NCT02271802 Completed - SCFA Metabolism Clinical Trials

Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids

Start date: June 2009
Phase: N/A
Study type: Interventional

In this placebo-controlled randomized parallel study the effects of a butyrate enema on plasma short-chain fatty acids (SCFA) concentrations and fluxes from portal drained viscera, liver and the splanchnic area are investigated

NCT ID: NCT02271776 Completed - Obesity Clinical Trials

GOS and Insulin Sensitivity

Start date: October 2014
Phase: N/A
Study type: Interventional

Based on our hypothesis that orally administered GOS will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective: To investigate the effects of a 12-week supplementation of GOS on peripheral insulin sensitivity and body weight control in obese adults with impaired glucose homeostasis.